Strategies for the inhibition of protein aggregation in human diseases. - Wikidata - wikimedia - TriplyDB

Strategies for the inhibition of protein aggregation in human diseases.

Strategies for the inhibition of protein aggregation in human diseases.

http://www.wikidata.org/entity/Q37733418

about

Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z Ubiquitous amyloids Dysferlin-peptides reallocate mutated dysferlin thereby restoring function Amyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms Drug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid Structures Suppressing mutation-induced protein aggregation in mammalian cells by mutating residues significantly displaced upon the original mutation Cis-suppression to arrest protein aggregation in mammalian cells.A revisited folding reporter for quantitative assay of protein misfolding and aggregation in mammalian cells.Techniques for Monitoring Protein Misfolding and Aggregation in Vitro and in Living Cells Constrained proper sampling of conformations of transition state ensemble of protein folding.Targeting RNA binding proteins involved in neurodegeneration.Mass spectrometry as an efficient tool for the characterization of amyloid β peptide 25-35 self-assembly species in aggregation and inhibition studies.Transthyretin cardiac amyloidoses in older North Americans.Opposing Effects of Cucurbit[7]uril and 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose on Amyloid β25-35 Assembly.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta.Heart failure with preserved ejection fraction in the elderly: scope of the problem.Interfacial self-assembly of amino acids and peptides: scanning tunneling microscopy investigation.Therapeutic targets associated to E-cadherin dysfunction in gastric cancer.Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers.Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process.HP-β-cyclodextrin as an inhibitor of amyloid-β aggregation and toxicity.Unique example of amyloid aggregates stabilized by main chain H-bond instead of the steric zipper: molecular dynamics study of the amyloidogenic segment of amylin wild-type and mutants.Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation Amyloid β-peptide 25-35 self-assembly and its inhibition: a model undecapeptide system to gain atomistic and secondary structure details of the Alzheimer's disease process and treatment.Inhibition of HEWL fibril formation by taxifolin: Mechanism of action.1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose Binds to the N-terminal Metal Binding Region to Inhibit Amyloid β-protein Oligomer and Fibril Formation.Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer's Amyloid β-Peptide Aggregation.Inhibiting and reversing amyloid-β peptide (1-40) fibril formation with gramicidin S and engineered analogues.The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon.Inhibiting, promoting, and preserving stability of functional proteinfibrils Synthesis and conformational studies of a stable peptidomimetic β-hairpin based on a bifunctional diketopiperazine turn inducer N-Acetyl-l-cysteine capped quantum dots offer neuronal cell protection by inhibiting beta (1–40) amyloid fibrillation

P2860

Q21562132-39F94546-E4D8-4ECB-A046-7B82A083CB6C Q27016014-E0648437-3A08-40E1-9BEE-9C88776541D1 Q27335454-3925C0F4-A41E-491F-A490-08676A5ADD94 Q27674676-E9550F1E-25FD-421E-AAE3-F118CCC54820 Q28259424-27E67027-7E39-4636-88B3-2B2960ED98C4 Q28547692-058EB1B0-7C6B-468E-AAF8-F70CF0FF2CFB Q30278991-7E65C784-A7A1-44AA-B334-5C3B2043F77F Q30380020-D4C247A2-BC74-4E4F-A822-6A3BC16FAAEB Q30416886-D224F130-CD1D-4B73-8099-B96A7526C54E Q30420104-3D5DE23B-DBAD-40C7-AA52-D64A967DD255 Q34764716-EEDC06AF-75A0-4A7A-A940-A6A477D6F9D2 Q34954162-6D55940D-991F-4875-AF47-D1089B3C428F Q35078911-556E131E-7AB2-41EF-A13F-D906912C1B23 Q35886169-2527C38B-2C39-45F8-9E30-F644F34FEFE8 Q36593981-5FE3C057-51C7-4A1E-AE94-AA4436AA6E15 Q36799584-566D1B45-82A3-47D7-889C-7E2F6034D02A Q37019530-19B6168B-AE48-461C-B3CE-B9234830A1DA Q37633991-554E0EB4-09BA-4FB5-897C-CE80EE9B3EEE Q37953253-17319B09-B58D-4E21-AF04-D002C4C738F5 Q38129925-CFA987F4-C2B9-436E-8CC7-178BDA089195 Q38184970-7328CC21-8147-431B-97DC-330B40407A03 Q38622861-2CECE91E-9586-44A8-B4DA-A7D6C41D3816 Q39112084-8DEBFAA0-451D-474C-B913-E9FF6B9B0637 Q39609556-8134510C-BCA6-40C2-B0CF-FA7C60AF64E1 Q39744550-F53C3B7D-A639-47F0-8F99-3980D8439EB6 Q39867365-816044FE-8D56-4094-82D9-B1A1803975A9 Q41664110-4AAE2927-46DD-41CD-BC97-8B29D750C5BD Q46262746-4BB3FDF6-EDDC-48AB-BA90-AACED576A5B4 Q46686323-6BC29751-0EF4-4C3A-9EDE-812283E49961 Q46797580-40E78AC2-109C-45A4-B44A-CB4778E77957 Q46864842-F7559DEB-46E1-4640-9488-841079310B19 Q50859830-E2E62009-1293-4777-8188-022632C3BBEC Q57364071-4EA9F2A1-0980-4554-B762-CA9C13DB3C45 Q58037802-BEFF289B-D912-4802-BCD3-11F226BC0363 Q58376450-CCB81FF3-A958-42D3-9720-2B7377D29836

P2860

Strategies for the inhibition of protein aggregation in human diseases.

http://www.wikidata.org/entity/Q37733418

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Strategies for the inhibition of protein aggregation in human diseases.

@en

Strategies for the inhibition of protein aggregation in human diseases.

@nl

type

label

Strategies for the inhibition of protein aggregation in human diseases.

@en

Strategies for the inhibition of protein aggregation in human diseases.

@nl

prefLabel

Strategies for the inhibition of protein aggregation in human diseases.

@en

Strategies for the inhibition of protein aggregation in human diseases.

@nl

P1433

Q37733418-5BC076D9-F4E2-4FBC-B5C4-2638826D93B1

P1476

Q37733418-5A797D00-4D01-40C4-8193-A6B4238EC555

P2860

Q37733418-0CEDBEF3-DBE6-4C6C-9FB1-BAB7081D478D

Q37733418-14135A6D-AF39-41D8-BB15-DFC190141624

Q37733418-1E510F4C-CED6-48C9-A9F6-0E93D4A928C3

Q37733418-29FCE436-C0DD-4898-8103-4DA0BFE16628

Q37733418-3FD2E738-0AB4-4CFD-9339-61CA2BA3D5D8

Q37733418-51519669-87AB-44E6-B952-CD7C1685BF3E

Q37733418-697B2D22-9A7A-48BD-AA05-3E6C07DC809A

Q37733418-7ED40A5D-9F2F-4DE5-9827-D2F423126CDE

Q37733418-F984F333-C05E-4BE8-ABBE-019FED91C3DC

Q37733418-FF9C81A6-0E57-4E18-AEEA-1A24897FC7B7

P304

Q37733418-0E422BB9-788A-4ED1-AB08-404F5908CC8C

P31

Q37733418-0FE20793-C5B2-40AF-BF26-8169BDCE0957

P356

Q37733418-00D8184C-BAFA-43AB-A35A-0102FEA1A356

P433

Q37733418-C7629B26-5B84-4368-8DF8-8487FC77E4DD

P478

Q37733418-17A005F0-07C8-4FFB-9DB0-A95347311666

P50

Q37733418-AD19F655-85F1-4A99-9DCF-961E7A82DA35

Q37733418-D872AD03-44D4-4C89-A837-395D373A8A89

P577

Q37733418-F5207447-6E2C-4EA2-AB02-FB1A25A94FAE

P698

Q37733418-6C6E85FD-6AFF-459C-9243-76E17295D5F7

P356

P1433

P1476

Strategies for the inhibition of protein aggregation in human diseases.

@en

P2860

Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target.

Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases.

A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model

Recent advance in immunotherapies for Alzheimer disease: with special reference to DNA vaccination.

Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss.

Pesticides: double exposure heightens Parkinson disease risk.

Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins--a role in nuclear localization.

Dietary antioxidants and Parkinson disease. The Rotterdam Study.

[A review for recent advances in AA amyloid research and therapeutic approach to AA amyloidosis complicating rheumatoid arthritis].

P304

1018-1035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CBIC.200900666

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Manuela Bartolini

Vincenza Andrisano

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20401887

http://www.w3.org/2001/XMLSchema#string